---
title: "Truist Securities maintains Buy rating on Arcus Biosciences, $41 price target"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302570324.md"
description: "Truist Securities maintains a Buy rating on Arcus Biosciences with a $41 price target, implying a 72.6% upside from the October 20 close of $23.75. The analyst cites strong clinical data for product candidates like Cas + Cabo and a robust pipeline with multiple Phase III programs as key drivers for potential revenue growth estimated at ~$3.2 billion."
datetime: "2026-10-21T13:11:18.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302570324.md)
  - [en](https://longbridge.com/en/news/302570324.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302570324.md)
generator: "portal-rs"
---

# Truist Securities maintains Buy rating on Arcus Biosciences, $41 price target

Truist Securities maintained their Buy rating on Arcus Biosciences's stock with a price target of $41.00.

The price target implies an upside of 72.6% from the Oct 20 close of $23.75.

**Key takeaways from the analyst note**

**Strong Clinical Data**: Arcus Biosciences is supported by promising clinical results, particularly with the efficacy of its product candidates like Cas + Cabo, which demonstrates a competitive edge in overall survival and progression-free survival compared to existing therapies, suggesting potential for market differentiation.

**Expanding Pipeline and Market Opportunity**: The company has a robust pipeline with multiple Phase III programs planned, indicating a strong potential for revenue growth, estimated to reach ~$3.2 billion. This potential, combined with a favorable setup for upcoming trials, reinforces confidence in its stock.

Explore more price target data and ratings for Arcus Biosciences on the .

**Disclaimer**

Select reference data provided by Benzinga. This information is not a recommendation for what you should do personally and does not constitute investment advice.

### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)

## Related News & Research

- [Arcus Biosciences (RCUS) Could Be 55% Undervalued As Third Quarter Losses Land](https://longbridge.com/en/news/304736643.md)
- [Arcus Biosciences Participates in Fireside Chat at Jefferies Global Healthcare Conference](https://longbridge.com/en/news/304008121.md)
- [These Analysts Revise Their Forecasts On Securitize Following Q3 Results](https://longbridge.com/en/news/305036514.md)
- [The Buffett Indicator Is Flashing Red. These 3 Dividend Stocks Could Be Safe Havens.](https://longbridge.com/en/news/304985751.md)
- [Results: Moderna, Inc. Confounded Analyst Expectations With A Surprise Profit](https://longbridge.com/en/news/304996083.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**